BioSpace News Archive

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announces that it has terminated certain related party agreements pertaining to its cannabis cultivation operation in Metro Vancouver.

Viela Bio, Inc. (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $47.00 per share

BioCryst Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share.

Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today announced publication of two papers in Science Translational Medicine (“STM”).

Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company’s management will present an overview and update, as well as host investor meetings, at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 4:00 p.m. ET.

Varian (NYSE: VAR) today announced that J. Michael Bruff, Chief Financial Officer, Chris Toth, President, Varian Oncology Systems, and Anshul Maheshwari, Vice President, Investor Relations and Treasurer will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference, scheduled for 11:00 a.m. Eastern Time on Tuesday, June 2, 2020.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic

Tetraphase Pharmaceuticals, Inc. announced that its Board of Directors has received a revised proposal from Melinta Therapeutics, Inc. amending its prior proposal to acquire the Company, and has determined that the Amended Melinta Proposal is a “Superior Offer” under the terms of the Agreement and Plan of Merger, dated March 15, 2020 and amended on May 27, 2020, to which the Company is a party with AcelRx Pharmaceuticals, Inc. and its merger subsidiary.

Shanghai Cell Therapy Group (SHCell) recently entered into a six-year research collaborative project with Professor Qi-Long Ying from the University of Southern California (USC).